Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

作者：Moericke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig W D; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M^*

来源：Leukemia, 2010, 24(2): 265-284.

DOI：10.1038/leu.2009.257

• acute lymphoblastic leukemia
• childhood
• long-term follow-up

Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin-Frankfurt-Munster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria and Switzerland. Probability of 10-year event-free survival (EFS) (survival) improved from 65% (77%) in study ALL-BFM 81 to 78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non-HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed reintensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients. Leukemia (2010) 24, 265-284; doi: 10.1038/leu.2009.257; published online 10 December 2009

• 出版日期2010-2